Preview

Diabetes mellitus

Advanced search

The role of phenofibrate in the treatment of microvascular complications of type 2 diabetes mellitus

https://doi.org/10.14341/2072-0351-5714

Abstract

Results of numerous studies give definitive evidence that phenofibrate affects activity of PPAR-a receptors in liver and thereby decreases the level oflipids responsible for the development of atherosclerosis (VLDL, small dense LDL); simultaneously, it increases the level of anti-atherogenic HDL.Activation of PPAR-a receptors in vascular cells decreases activity of inflammation markers, such as C-reactive protein, TNF-a, IL-6, fibrinogen,etc. These effects of phenofibrate eventually lead to reduced risk of macro- and microvascular diabetic complications.

About the Authors

Larisa Viktorovna Koshel'
I.M. Sechenov Moscow Medical Academy, Moscow


Tatiana Ivanovna Romantsova
I.M. Sechenov Moscow Medical Academy, Moscow


References

1. Keech A.C., Mitchell P., Summanen P. A. еt al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial //Lancet. - 2007. - 370. - P. 1687-1697.

2. Fruchart J.C., Respe E., Lefebvre A.M., et al. Modulation of rat liver apolipoprotein gene expression and serum lipid levels by tetradecylthioacetic acid via PPARalpha activation //J. Lipid Res. - 1999. - 40(11). - P. 2099-2110.

3. Chapman M.G. Fibrates in 2003: therapeutic action in atherogenic dyslipidemia and future perspectives //Atherosclerosis. - 2003. - 171. - P. 1-13.

4. Plutzky J. PPARs as therapeutic targets: reverse ardiology? //Science. - 2003. - 302. - P. 406-07.

5. Ziozenkova O., Perrey S., Asatryan L., at al. Lipolysis of triglyceridrich lipoproteins generates PPAR ligands: evidence for an anti-inflammatory role for lipoprotein lipase // Proc. Natl. Acad. Sci. USA. - 2003. - 100. - P. 2730-2735.

6. Marx N., Kehrle B., Kohlhammer K., at al. PPAR activators as anti-inflammatory mediators in human T lymphocytes. Implications for atherosclerosis and transplantation-associated arteriosclerosis// Circ. Res. - 2002. - 90. - P. 703-710.

7. Brownlee M., Banting Lecture 2004. The pathobiology of diabetic complications. A unifyingmechanism //Diabetes. - 2005. - 54. - P. 1615-1625.

8. Chew E.Y., Klein M.L., Ferris F.L. еt al. Association of elevated serum lipid levels with retinal hard exudates in diabetic retinopathy. ETDRS Report 22 //Arch. Ophthalmol. - 1996. - 114. - P. 1097-84.

9. Thomas M.С. Serum lipids and the progression of nephropathy in type 1 diabetes // Diabetes care. - 2006. - 29 (2). - P. 317-322.

10. Keating G.M., Croom K.F. Fenofibrate. A Review of its Use in Primary Dyslipidaemia, the Metabolic Syndrome and Type 2 Diabetes mellitus. Drugs 2007; 67(1); 121-153.

11. Diabetes Atherosclerosis Intervention Study Investigators. Effect of fenofibrate on progression of coronary artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357: 905-10.

12. Lyons T.J., Jenrins A.J., Zheng D. et.al. Diabetic retinopathy and serumlipoprotein subclasses in the DCCT/EDIC cohort //Invest. Ophthalmol. Vis. Sci. - 2004. - 45. - P. 910-8.

13. Kaysen G.A., Eiserich J.P. The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction //J. Am. Soc. Nephrol. - 2004. - 15. - P. 538-548.

14. Keech A., Simes R.J., Barter P. et.al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial // Lancet. - 2005. - 26. - P. 1849-61.

15. Rajamani K., Colman P. G., Best J.D. et.al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (the FIELD study): a prespecified analysis of randomized controlled trial // Lancet. - 2009. - 373. - P. 1780-1788.

16. Ansquer J.C., Foucher C., Rattier S. et.al. Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: Results from the Diabetes Atherosclerosis Intervention Study (DAIS) // Am. J. Kidney Dis. - 2005. - 45. - P. 485-493.

17. Ferrara N. Role of vascular endothelial growth factor in regulation of physiological angiogenesis //Am. J. Physiol. 2001, 280: P. 1358-66.

18. Kim J., Aim J.H., Kim J.H. et.al. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway // ExP. Eye. Res. - 2007. - 84. - P. 886-893.

19. Malic J., Melenovsky V., Widilerle D. et.al. Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidemia (fenofibrate versus atorvastatin trial - FAT) //Cardiovasc. Res. - 2001. - 52. - P. 290-298.

20. Demircan N., Safran B.G., Soylu M. et.al. Determination of vitreus interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy// Eye. - 2006. - 20. - P. 1366-1369.

21. Ryan K.E., McCance D.R., Powell L. et.al. Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men //Atherosclerosis. - 2006. - 194. - P. 123-130.

22. Losada M., Alio J.L. Malondialdehyde serum concentration in type 1 diabetic with and without retinopathy //Doc. Ophthalmol. - 1997. - 93. - P. 223-229.

23. Chen L., Zhang J., Zhang Y. Improvement of inflammatory responses associated with NF-kappaB pathway in kidneys from diabetic rats //Inflamma. Res. - 2008. - 57. - P. 199-204.

24. Park C.W., Zhang Y., Zhang X. et.al. PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice //Kidney Int. - 2006. - 69. - P. 1511-1517.

25. Ganessaratem K. Balendiran, Balakrishnan Rajkumar. Fibrates inhibit aldose reductase activity in the forward and reverse reactions //Biochemical Pharmacology. - 2005. - 70. - P. 1653-1663.

26. Дедов И.И., Шестакова М.В. Сахарный диабет. М., 2003.

27. Maison P. , Mennen L., Sapinho D., et.al. A pharmacoepidemical assessment of the effect of statins and fibrates on fibrinogen concentration // Atherosclerosis. - 2002. - 160 (1). - P. 155-160.

28. Fujisawa T., Ikegami H., Yamato E. et.al. Association of plasma fibrinogen level and blood pressure with diabetic retinopathy, and renal complications associated with proliferative diabetic retinopathy, in type 2 diabetes mellitus //Diabet. Med. - 1999. - 16. - P. 522-526.


Review

For citations:


Koshel' L.V., Romantsova T.I. The role of phenofibrate in the treatment of microvascular complications of type 2 diabetes mellitus. Diabetes mellitus. 2009;12(4):99-103. (In Russ.) https://doi.org/10.14341/2072-0351-5714

Views: 8176


ISSN 2072-0351 (Print)
ISSN 2072-0378 (Online)